Overview

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Aim 1.Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone system impairs glycemic control via effects on insulin sensitivity and insulin secretion. Aim 2. Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone system impairs insulin secretion and insulin sensitivity via an mineralocorticoid-receptor dependent mechanism.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Medical Center
Treatments:
Amlodipine